Q1 Earnings Forecast for Neurogene Issued By Leerink Partnrs

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Neurogene in a research note issued to investors on Monday, March 24th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($1.12) per share for the quarter. The consensus estimate for Neurogene's current full-year earnings is ($4.27) per share. Leerink Partnrs also issued estimates for Neurogene's Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($4.76) EPS and FY2026 earnings at ($6.03) EPS.

Neurogene (NASDAQ:NGNE - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.05. The company had revenue of $0.93 million for the quarter.

Several other equities analysts have also commented on NGNE. HC Wainwright decreased their price target on Neurogene from $55.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 25th. William Blair reiterated an "outperform" rating on shares of Neurogene in a report on Tuesday, March 25th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $59.80.

Remove Ads

Neurogene Trading Down 16.4 %

NASDAQ NGNE traded down $2.39 on Thursday, reaching $12.14. 62,339 shares of the company were exchanged, compared to its average volume of 209,502. The business's fifty day moving average price is $16.88 and its 200 day moving average price is $28.68. The stock has a market capitalization of $180.27 million, a P/E ratio of -2.88 and a beta of 1.01. Neurogene has a fifty-two week low of $12.13 and a fifty-two week high of $74.49.

Institutional Trading of Neurogene

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. bought a new stake in shares of Neurogene during the fourth quarter valued at about $71,000. China Universal Asset Management Co. Ltd. bought a new position in Neurogene during the fourth quarter valued at approximately $72,000. Virtus ETF Advisers LLC lifted its holdings in Neurogene by 45.1% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,183 shares of the company's stock worth $73,000 after purchasing an additional 989 shares during the last quarter. BNP Paribas Financial Markets increased its position in Neurogene by 192.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company's stock worth $91,000 after buying an additional 1,429 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in shares of Neurogene by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 5,444 shares of the company's stock worth $124,000 after purchasing an additional 1,397 shares in the last quarter. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO Christine Mikail Cvijic sold 4,501 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the sale, the chief financial officer now owns 72,343 shares in the company, valued at approximately $1,225,490.42. This represents a 5.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 9.92% of the company's stock.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.